

**SUPRIYA LIFESCIENCE LIMITED**  
CIN No: LS1900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: LS1900MH2008PLC180452  
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com



(₹ In million)


Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Half year ended	Half year ended	Year ended
		30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 Audited
<b>Income</b>							
I	Revenue from Operations	1,998.33	1,450.74	1,661.02	3,449.07	3,267.28	6,964.85
II	Other Income	27.25	26.74	25.18	53.99	47.42	98.15
III	<b>Total Income</b>	<b>2,025.58</b>	<b>1,477.48</b>	<b>1,686.20</b>	<b>3,503.06</b>	<b>3,314.70</b>	<b>7,063.00</b>
2	Expenses						
a)	Cost of Materials Consumed	606.83	437.76	615.81	1,044.59	1,173.08	2,324.36
b)	Purchase of Stock in Trade	-	-	-	-	-	-
c)	Change in Inventories of finished goods, work in progress & stock in trade,	(49.53)	(120.04)	(156.06)	(169.57)	(227.36)	(212.59)
d.)	Employee benefit expenses	244.81	226.88	196.85	471.69	397.70	805.49
e.)	Finance Cost	4.15	5.12	4.27	9.27	7.62	16.86
f.)	Depreciation & amortisation expense	66.39	64.51	47.44	130.90	94.00	204.44
g.)	Other expenditure	469.75	389.13	357.25	858.88	651.28	1,439.93
IV	<b>Total Expenses</b>	<b>1,342.40</b>	<b>1,003.36</b>	<b>1,065.56</b>	<b>2,345.76</b>	<b>2,096.32</b>	<b>4,578.19</b>
V	Profit/(loss) before Exceptional Items & Tax (III-IV)	683.18	474.12	620.64	1,157.30	1,218.38	2,484.80
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Profit/(loss) before Tax (V-VI)</b>	<b>683.18</b>	<b>474.12</b>	<b>620.64</b>	<b>1,157.30</b>	<b>1,218.38</b>	<b>2,484.80</b>
VIII	<b>Tax Expense</b>						
a)	Current Tax	151.58	105.35	154.46	256.93	301.13	566.57
b)	Deferred Tax	27.33	20.87	4.69	48.20	9.33	38.66
IX	<b>Profit/(Loss) for the period from Continuing Operations (VII-VII)</b>	<b>504.27</b>	<b>347.90</b>	<b>461.49</b>	<b>852.17</b>	<b>907.92</b>	<b>1,879.58</b>
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	<b>Profit/(Loss) for the period (IX+XII)</b>	<b>504.27</b>	<b>347.90</b>	<b>461.49</b>	<b>852.17</b>	<b>907.92</b>	<b>1,879.58</b>
XIV	Other Comprehensive Income						
A	(i) Items that will not be reclassified to profit or loss	0.45	(2.87)	(2.90)	(2.42)	(3.64)	(1.67)
(ii)	Income Tax relating to items that will not be reclassified to profit or loss	(0.11)	0.72	0.73	0.61	0.92	0.42
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii)	Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>504.61</b>	<b>345.75</b>	<b>459.33</b>	<b>850.36</b>	<b>905.20</b>	<b>1,878.33</b>
XVI	Earnings per equity Share (for continuing operation):						
(1)	Basic (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35
(2)	Diluted (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35
XVII	Earnings per equity Share (for discontinued operation):						
(1)	Basic (In ₹)	-	-	-	-	-	-
(2)	Diluted (In ₹)	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
(1)	Basic (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35
(2)	Diluted (In ₹)	6.27	4.32	5.71	10.59	11.25	23.35

See accompanying notes to the financial statements:

Notes:-

1. The unaudited standalone financial results of the Company for the quarter ended September 30, 2025 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above unaudited standalone financial results of the Company for the quarter ended September 30, 2025 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on November 12, 2025.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The company does not have any subsidiary/associate/joint venture company as on September 30, 2025.
5. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.

Place :- Mumbai  
Date :- November 12, 2025

For Supriya Lifescience Limited  
  
Dr. Saloni Wagh  
Managing director  
DIN: 08491410



Particulars	September 30, 2025	March 31, 2025
<b>ASSETS</b>		
<b>Non-current assets</b>		
(i) Property, plant and equipment	4,518.95	4,468.32
(ii) Right to Use Asset	44.09	46.45
(iii) Capital Work in progress	1,724.95	1,480.15
(iv) Intangible Assets	12.14	13.89
(v) Financial Assets		
- Investments	565.48	632.41
- Loans and Advances	-	-
(vi) Other Non- Current Assets	113.42	111.54
<b>Total Non-current assets</b>	<b>6,979.04</b>	<b>6,752.76</b>
<b>Current assets</b>		
(i) Inventories	1,428.13	1,183.49
(ii) Financial Assets		
- Loans and Advances	8.20	9.27
- Trade receivables	1,551.17	1,343.62
- Cash and cash equivalents	992.63	760.57
- Bank balances other than (iii) above	39.52	30.97
- Other Financial Assets	50.28	7.11
(iii) Other current assets	1,000.61	1,035.35
<b>Total Current Assets</b>	<b>5,050.54</b>	<b>4,370.38</b>
<b>TOTAL ASSETS</b>	<b>12,029.58</b>	<b>11,123.14</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(i) Equity share capital	160.97	160.97
(ii) Other equity	10,657.00	9,806.63
<b>Total Equity</b>	<b>10,817.97</b>	<b>9,967.60</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
(i) Financial Liabilities		
- Lease Liabilities	49.32	50.57
- Other financial liabilities	-	-
(ii) Provisions	15.20	13.18
(iii) Deferred tax Liabilities	318.38	270.18
<b>Total Non-Current Liabilities</b>	<b>382.90</b>	<b>333.93</b>
<b>Current liabilities</b>		
(i) Financial liabilities		
- Lease Liabilities	3.00	3.23
- Trade payables	-	-
Micro Enterprises and Small Enterprises		
Other than micro and small enterprises	763.52	745.46
- Other financial liabilities	5.74	17.59
(ii) Provisions	11.39	11.93
(iii) Other current liabilities	45.06	43.41
<b>Total Current Liabilities</b>	<b>828.71</b>	<b>821.62</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>12,029.58</b>	<b>11,123.14</b>




Supriya Lifescience Ltd

CIN No: L51900MH2008PLC180452

Cash flow statement for the period ended September 30, 2025

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	September 30, 2025	September 30, 2024
<b>A CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before tax	1,157.30	1,218.39
<b>Adjustments for</b>		
Depreciation and Amortization	130.90	94.00
Interest Income (Net of Expenses)	(42.02)	(18.85)
Dividend Received	-	(0.05)
Employee Benefit	(0.94)	7.01
Loss on Sale of fixed Assets	0.30	0.06
<b>Operating profit before working capital changes</b>	<b>1,245.54</b>	<b>1,300.56</b>
<b>Adjustments for movement in working capital</b>		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	(207.54)	59.57
Inventories	(244.64)	(227.36)
Other Non Current & Current Assets	32.86	83.15
Other Non Current & Current Financial Assets	(23.17)	18.62
Loans and Advances	1.07	(0.83)
	(441.42)	(66.85)
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	18.06	28.37
Other Non Current & Current Financial Liabilities	(11.86)	14.01
Other Non Current & Current liabilities	(0.17)	(53.34)
	6.02	(10.96)
(Income tax paid)/net of refund	(254.50)	(301.13)
<b>Net Cash generated from Operating Activities</b>	<b>555.65</b>	<b>921.62</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed Assets	(422.49)	(758.25)
(Purchase)/ Sale of Investments	66.93	(86.92)
Interest Income	51.28	19.80
Dividend Received	-	0.05
<b>Net Cash generated/(outflow) from Investing Activities</b>	<b>(304.29)</b>	<b>(825.32)</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES</b>		
Finance Cost	(9.26)	(0.95)
Dividend Paid	-	-
Repayment of Lease liability	(1.49)	(1.78)
<b>Net Cash generated from Financing Activities</b>	<b>(10.75)</b>	<b>(2.73)</b>
<b>Net Increase/(Decrease) in Cash and Cash equivalents</b>	<b>240.61</b>	<b>93.59</b>
<b>Cash and Cash Equivalents at the end of previous period</b>	<b>791.54</b>	<b>749.56</b>
<b>Cash and Cash Equivalents as at the end of the reporting period</b>	<b>1,032.15</b>	<b>843.14</b>